Particles for Targeted Delivery and Uses in Managing Bleeding or Blood Clotting

Abstract

This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating, encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.

1 . A method of reducing blood clotting comprising administering an effective amount of particles to a subject in need thereof,
 wherein the particles have a core comprising tissue plasminogen activator (tPA) encapsulated in a coating comprising:   a) a cationic polymer layer, wherein the cationic polymer layer comprises poly-L-lysine;   b) an anionic polymer layer, wherein the anionic polymer layer comprises poly-L-glutamic acid, and the cationic polymer layer is over a polysaccharide layer;   c) an outer layer exposing fibrinogen on the outer surface, wherein the anionic polymer layer is under the outer layer; and   wherein the polysaccharide is a dextran.   
     
     
         2 . The method of  claim 1 , wherein the subject is diagnosed heart attack. 
     
     
         3 . The method of  claim 1 , wherein the subject is diagnosed with stroke. 
     
     
         4 . The method of  claim 1 , wherein the subject is diagnosed with thrombosis. 
     
     
         5 . The method of  claim 1 , wherein the subject is diagnosed with pulmonary thrombosis. 
     
     
         6 . The method of  claim 1 , wherein the subject is diagnosed with deep vein thrombosis. 
     
     
         7 . The method of  claim 1 , wherein the subject is diagnosed with Factor V Leiden. 
     
     
         8 . The method of  claim 1 , wherein the tissue plasminogen activator is a human recombinant form. 
     
     
         9 . The method of  claim 1 , wherein the particles are administered intravenously.